trail neutralizing antibody (R&D Systems)
R&D Systems is a verified supplier 
R&D Systems manufactures this product 
94
Structured Review
R&D Systems
trail neutralizing antibody
Trail Neutralizing Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 27 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+trail/Human+TRAIL%2FTNFSF10+Antibody/pmc13111737-305-11-15
Average 94 stars, based on 27 article reviews
Trail Neutralizing Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 27 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+trail/Human+TRAIL%2FTNFSF10+Antibody/pmc13111737-305-11-15
Average 94 stars, based on 27 article reviews
trail neutralizing antibody - by Bioz Stars,
2026-09
94/100 stars
Images
Related Articles
Recombinant:Article Title: Noncompetitive Allosteric Antagonism of Death Receptor 5 by a Synthetic Affibody Ligand. Article Snippet: .. Huh-7 cells grown in 96-well plates were treated with recombinant Article Title: Circulating Tumor Cells Develop Resistance to TRAIL-Induced Apoptosis Through Autophagic Removal of Death Receptor 5: Evidence from an In Vitro Model Article Snippet: .. The cells were treated with the recombinant Article Title: TRAIL-Based Therapies Efficacy in Pediatric Bone Tumors Models Is Modulated by TRAIL Non-Apoptotic Pathway Activation via RIPK1 Recruitment. Article Snippet: TC-71 cells were cultured in Rosewell Park Millenium Institute (RPMI, Lonza) medium with 5% FBS and 2 mmol/L L-glutamine. .. Two thousand cells per well were seeded into 96-well plates and cultured for 72 h in the presence of increasing concentrations of recombinant Article Title: In vitro and in vivo discrepancy in inducing apoptosis by mesenchymal stromal cells delivering membrane-bound tumor necrosis factor-related apoptosis inducing ligand in osteosarcoma pre-clinical models. Article Snippet: Background: Osteosarcoma (OS) is the most frequent pediatric malignant bone tumor.. OS patients have not seen any major therapeutic progress in the last 30 years, in particular in the case of metastatic disease, which requires new therapeutic strategies.. The pro-apoptotic cytokine Tumor necrosis factor (TNF) Related Apoptosis Inducing Ligand (TRAIL) can selectively kill tumor cells while sparing normal cells, making it a promising therapeutic tool in several types of cancer. Article Title: Identification of a marine-derived sesquiterpenoid, Compound-8, that inhibits tumour necrosis factor-induced cell death by blocking complex II assembly. Article Snippet: Tongji University Cancer Center, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China Tongji University School of Medicine, Shanghai, China School of Pharmacy, Second Military Medical University, Shanghai, China School of Pharmacy, Nanchang University, Nanchang, China Shanghai Power Hospital, Shanghai, China Department of ORL-HNS, Shanghai Fourth People's Hospital, Tongji University School of Medicine, Shanghai, China The Royal College of Surgeons in Ireland, Dublin, Ireland The Royal College of Surgeons of England, London, UK Center of Excellence for Cancer and Inflammation, Department of Clinical Chemistry, Faculty of Allied Health Sciences, Chulalongkorn University, Bangkok, Thailand Ningbo Institute of Marine Medicine, Peking University, Beijing, China Multiple Displacement Amplification:Article Title: Circulating Tumor Cells Develop Resistance to TRAIL-Induced Apoptosis Through Autophagic Removal of Death Receptor 5: Evidence from an In Vitro Model Article Snippet: .. The cells were treated with the recombinant Cell Culture:Article Title: TRAIL-Based Therapies Efficacy in Pediatric Bone Tumors Models Is Modulated by TRAIL Non-Apoptotic Pathway Activation via RIPK1 Recruitment. Article Snippet: TC-71 cells were cultured in Rosewell Park Millenium Institute (RPMI, Lonza) medium with 5% FBS and 2 mmol/L L-glutamine. .. Two thousand cells per well were seeded into 96-well plates and cultured for 72 h in the presence of increasing concentrations of recombinant Article Title: In vitro and in vivo discrepancy in inducing apoptosis by mesenchymal stromal cells delivering membrane-bound tumor necrosis factor-related apoptosis inducing ligand in osteosarcoma pre-clinical models. Article Snippet: Background: Osteosarcoma (OS) is the most frequent pediatric malignant bone tumor.. OS patients have not seen any major therapeutic progress in the last 30 years, in particular in the case of metastatic disease, which requires new therapeutic strategies.. The pro-apoptotic cytokine Tumor necrosis factor (TNF) Related Apoptosis Inducing Ligand (TRAIL) can selectively kill tumor cells while sparing normal cells, making it a promising therapeutic tool in several types of cancer. Incubation:Article Title: Preclinical studies of a death receptor 5 fusion protein that ameliorates acute liver failure. Article Snippet: Acute liver failure (ALF) is a life-threatening disease with a high mortality rate.. There is an urgent need to develop new drugs with high efficacy and low toxicity.. In this study, we produced a pharmaceutical-grade soluble death receptor 5 (sDR5)-Fc fusion protein for treating ALF and evaluated the pharmacology, safety, pharmacokinetics, efficacy, and mechanisms of sDR5-Fc in mice, rats, and cynomolgus monkeys. sDR5-Fc bound with high affinity to both human and monkey tumor necrosis factorrelated apoptosis-inducing ligand (TRAIL) effectively blocked TRAIL-induced apoptosis in vitro and significantly ameliorated ALF induced by concanavalin A (Con A) in mice. |
